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CASE REPORT
Amiodarone is a benzofuran derivative with antiar-
rhythmic and vasodilatory properties which has
been used since 1967 as an antiarrhythmic agent.
However, a variety of cardiac and extracardiac side
effects have been attributed to this drug such as
corneal microdeposit, hypothyroidism, hyperthyro-
idism, pulmonary toxicity, symptomatic bradycar-
dia, gastrointestinal disturbances, hepatic disease,
bone marrow depression, peripheral neuropathy
and dermatitis.1 Among these, amiodarone-related
pulmonary toxicity is the most serious of the extra-
cardiac side effects. Amiodarone toxicity was first
reported in 1980.2 The reported outcome in pa-
tients who have amiodarone pneumonitis has
ranged from total resolution to death. However,
low-dose (200 mg/day) amiodarone is considered
to be free of serious side effects.3 We report a series
of three patients with pulmonary pneumonitis
during low-dose amiodarone therapy to empha-
size that even low-dose amiodarone could lead to
pulmonary effects. This result could remind us of
detecting amiodarone pneumonitis in the early
stage even under low dosage usage.
Case Reports
The clinical records of three patients who received
low-dose amiodarone with pulmonary pneumoni-
tis are presented.
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Amiodarone-related pneumonitis is a potentially limiting factor for amiodarone usage. However, it is believed
that amiodarone-related pneumonitis is unlikely to occur during low-dose and short courses of therapy. We re-
port three patients who received low-dose amiodarone, 200 mg/day, for an average of 6.6 months and who de-
veloped amiodarone-related pneumonitis. All patients were male with age of 75, 93 and 85, respectively, and
had the habit of cigarette smoking. The initial presentation was dyspnea without symptoms and signs of heart
failure. Their chest radiographs showed diffuse interstitial pneumonitis pattern and chest computed tomogra-
phy scan also confirmed interstitial pneumonitis. Treatment included cessation of amiodarone and corticos-
teroid usage. All patients improved symptomatically by early detection and early treatment. This case report
implies that old age and possible pre-existing pulmonary abnormalities caused by smoking could be associ-
ated with amiodarone-related pulmonary toxicity. Clinicians must remain alert to detect amiodarone-related
pneumonitis even under low dosage and short duration of amiodarone usage. Immediate withdrawal of
amiodarone and prompt steroid therapy will ensure full recovery. [J Formos Med Assoc 2007;106(5):411–417]
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Case 1
A 75-year-old man was admitted to the hospital in
June 2005 because of non-productive cough and
increasing dyspnea for 1 week. He was an ex-smoker
and was diagnosed with non-ST elevation myocar-
dial infarction, inferior wall, Killip I status post
percutaneous transluminal coronary angioplasty
to left circumflex coronary artery in 1998. For the
past 9 months, he had been diagnosed with
paroxysmal atrial fibrillation and amiodarone
had been prescribed for rhythm control, initially at
a loading dose of 900 mg, which was then reduced
to 200mg daily. On physical examination, bilateral
basal rales were auscultated. The results of routine
laboratory tests and autoimmune profiles (anti-
nuclear antibody, 1:40-; C3, 100.0 mg/dL; C4,
28.0 mg/dL) were within normal limits. The chest
radiograph (Figure 1A) revealed fibrotic change
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Figure 1. (A) Chest radiograph of patient 1 obtained on admission shows hyperinflation with chronic infiltration over 
bilateral lungs and increasing bilateral lung marking. (B) Chest radiograph of patient 1 obtained 10 days after admission
shows improving infiltration in bilateral lower lung fields. (C) Chest radiograph of patient 3 obtained on admission shows
diffuse and irregular increased lung markings in both lower lungs. (D) Chest radiograph of patient 3 obtained 9 months
after admission shows linear interstitial infiltrations of left lower lung field improving.
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of bilateral lung parenchyma superimposed in-
creasing density, especially at bilateral peripheral
regions. Chest computed tomography (CT)
(Figure 2A) showed multiple ground-glass opaci-
ties in both lungs. Transthoracic echocardiogram
showed good left ventricular (LV) contractility
with a LV ejection fraction of 79%. Pulmonary
function test showed restrictive ventilatory defect
and impairment of diffusion capacity (Table 1).
Infection workup was performed and neither bac-
terial nor atypical pathogens were isolated. After
discontinuation of amiodarone and treatment
with systemic steroid (intravenous methylpredni-
solone [Solu-medrol, 40 mg/vial] 160 mg/day
initially for 3 days, then reduced to 40 mg daily
for 1 week, steroid was gradually tapered to 
oral prednisolone 20 mg/day for 1 month), 
there was rapid improvement in breathlessness
with return to normal exercise tolerance within 
2 months. Serial chest radiographs (Figure 1B)
showed clearing of pulmonary infiltration with
complete resolution.
Case 2
A 93-year-old man was admitted to hospital 
in August 2001 because of dyspnea and non-
productive cough. The symptoms had progressed
for 1 week. He was also an ex-smoker and had a
history of ventricular tachycardia episodes. Amio-
darone had been prescribed since April 2001
(200 mg/day). On examination, wheezing was
heard over bilateral lower lung fields. Leukocytosis
(white blood cell count, 15,280/μL; segments,
84%; eosinophils, 0%; lymphocytes, 4%) and 
elevation of C-reactive protein (24.6 mg/dL) were
noted. The results of biochemical tests were nor-
mal. Chest radiography showed increased diffuse
reticular infiltration in bilateral basal lungs. The
high resolution CT of the chest without contrast
enhancement showed pulmonary emphysema and
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Figure 2. (A) Chest computed tomography (CT) of patient 1 (with contrast medium, lung window) obtained on admission
shows multiple interstitial infiltrations. (B) Chest CT of patient 3 (without contrast medium, lung window) obtained on admis-
sion shows fibrotic patches with honeycomb appearance in both lungs.
Table 1. Patient 1 pulmonary function test
Observed Predicted % Predicted
% FEV1.0 74.9 76.1 98.4
TLC (L) 3.42 4.42 77.4
RV (L) 1.20 1.70 70.6
DLCO (mL/min/mmHg) 11.02 16.78 65.7
% FEV1.0 = forced expiratory volume in 1 second; TLC = total lung capacity; RV = residual volume; DLCO = diffusing capacity of the lung
for carbon monoxide.
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prominent interstitial pattern of lung parenchyma
with predominate reticulation and thickening of
interlobular septa. The interstitial process was
most evident at both lower lobes. The picture 
was consistent with interstitial pneumonitis. The
density of the liver parenchyma (about 60–70 di-
hydrouridine [HU]) increased compared with
normal soft tissue density (about 25–40 HU).
Transthoracic echocardiography showed good LV
ejection fraction. Initially, the patient accepted em-
pirical antibiotic (ampicillin sodium/sulbactam)
treatment for suspected pneumonia, but he
showed no clinical improvement. Due to the his-
tory of amiodarone use, the possibility of amio-
darone-related interstitial pneumonitis was highly
suspected. The patient had both oxygenation and
pulmonary compliance improvement after cessa-
tion of amiodarone and steroid usage (intravenous
methylprednisolone [Solu-medrol, 40 mg/vial]
120 mg/day initially for 10 days, which was then
reduced to 40 mg daily for 3 weeks).
Case 3
An 85-year-old man was an ex-smoker and diag-
nosed with paroxysmal atrial fibrillation in
December  1999. Amiodarone 200 mg/day had
been prescribed for 6 months. He suffered from ex-
ertional dyspnea and cough without sputum in
May 2000. On examination, breath sounds were
clear over bilateral lung fields. The results of rou-
tine laboratory examinations were within normal
limits. The chest radiograph (Figure 1C) showed
linear interstitial infiltrations of bilateral lower lung
fields and chest CT (Figure 2B) showed fibrotic
change in both lungs and confluent fibrosis was
especially noted in both lower lungs. Transthoracic
echocardiogram showed fair LV contractility (LV
ejection fraction, 56%). Under the impression of
amiodarone-related pneumonitis, amiodarone was
stopped after admission and oral steroid was given
(prednisolone, 30 mg/day for 1 week). Infection
workup finally showed no positive results. The
symptoms then improved and oral steroid (pred-
nisolone 10 mg/day) was used for 2 months.
Follow-up chest radiograph (Figure 1D) showed
clearing of pulmonary infiltration.
Discussion
Amiodarone had been increasingly used in the
treatment of supraventricular, ventricular arrhyth-
mias and nonischemic cardiomyopathy. However,
there have been many reports of side effects 
occurring during treatment. It has been difficult
to predict which patients are at risk for the develop-
ment of amiodarone-related toxicity. Amiodarone-
related pulmonary toxicity affects 6% of patients
at a daily dose of 400 mg or more over 2 or more
months, with a mortality rate of 10–20%,4 and
therefore low-dose therapy has been deemed a safe
alternative.5 We performed a retrospective electro-
nic chart search of our chart records by using the
key words amiodarone pulmonary pneumonitis
between 1996 and 2005. Approximately 73,530
medical records were searched by this method.
We reviewed the charts of the patients who re-
ceived amiodarone to evaluate the diagnosis of
amiodarone pneumonitis. Only three patients as-
sociated with amiodarone pneumonitis were iden-
tified during these 10 years. Most different from the
previous studies of amiodarone-related pneumoni-
tis in Caucasians (Table 2)6–12 is that our patients
were all receiving low-dose amiodarone (200
mg/day), for an average of 6.6 months prior to
developing pneumonitis (cumulative dose range,
30–54 g). That might indicate that Asian people
have high possibility of amiodarone-related pul-
monary toxicity compared to Caucasians, even
under low-dose amiodarone treatment. The mech-
anisms underlying the myriad toxic effects of
amiodarone on the lungs are complex and may
involve both direct toxic effects of free radicals
on cells and indirectly by inflammatory mecha-
nisms. Besides, there were no other medications
known to be associated with pulmonary toxicity
in our patients and all had the habit of cigarette
smoking and the average age of our patients was
84.3 years (range, 75–93). Other factors in addi-
tion to dose might also contribute to the pulmo-
nary toxicity in these patients with amiodarone
pneumonitis. Old age and possible pre-existing
pulmonary disorders caused by cigarette smok-
ing might be recognized as predisposing factors
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too. This observation suggested a possible rela-
tionship between low-dose amiodarone in Asian
people, old patients and cigarette smoking. But
further data should be collected to prove this
point of view.
Amiodarone-related pneumonitis is diagnosed
by the following criteria: (1) initial presentation as
worsening dyspnea; (2) chest radiograph with dif-
fuse interstitial or alveolar infiltrates; (3) pulmon-
ary function with decline > 15% in the diffusing
capacity of the lung for carbon monoxide or total
lung capacity; (4) ruling out congestive heart fail-
ure; (5) bronchoalveolar lavage fluid with “foamy”
cytoplasm in alveolar macrophages known as
phospholipidosis and CD8+ lymphocytosis; (6)
pathologic findings with pulmonary interstitium
inflammation, fibrosis, pneumocyte hyperplasia,
and hyaline membranes; and (7) drug withdrawal
with or without steroid therapy reverses some 
or all of the abnormalities.13 Our patients were
diagnosed with amiodarone-related pneumonitis
by clinical symptoms, examinations, radiographs,
laboratory investigations, echocardiograms and
treatment courses. The patients’ data are summa-
rized in Table 3. Dsypnea, particularly with exer-
tion, has been the most commonly reported
symptom of amiodarone pneumonitis and was
the presenting complaint in our patients. All the
patients’ radiographic abnormalities disclosed
the characteristic findings of nonspecific and dif-
fuse interstitial infiltration.14 In patient 2, the
Hounsfield unit of the liver (60–70 HU) was
higher than soft tissue density (25–40 HU) and
that might be due to deposition of amiodarone
Table 3. Patients’ clinical data
Patient 1 Patient 2 Patient 3
Gender Male Male Male
Age (yr) 75 93 85
Arrhythmia AF VF AF
Dose (mg/d) 200 200 200
Duration (mo) 9 5 6
Cumulative dose (g) 54 30 36
Symptoms Dyspnea, non-productive Dyspnea, non-productive Dyspnea, non-productive 
cough cough cough
Smoking 1 ppd > 10 yr 1/2 ppd > 10 yr < 1 ppd > 10 yr
quit for 20 yr quit for 30 yr quit for 50 yr
Lung function Restrictive pattern Nil Nil
UCG (LVEF) 79% 70% 56%
Steroid Yes Yes Yes
Outcome Improved Improved Improved
AF = atrial fibrillation; VF = ventricular fibrillation; ppd = pack per day; LVEF = left ventricular ejection fraction.
Table 2. Amiodarone-related pneumonitis
Reference Amiodarone dose (mg/d) Total dose (g) Time to recovery (mo)
5 600–1400 14.6–142.2 1.5–4
6 400–600 * 2
7 400–800 * *
8 400–800 * 3.5
9 400–800 20.8–369 *
10 600–1400 144–225 3
11 300–900 * *
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in the liver parenchyma. In the same way, amio-
darone could deposit in the lung parenchyma as
well at the same time. That might induce pul-
monary toxicity of amiodarone and this radio-
graphic finding could be used in the diagnosis of
amiodarone-related pneumonitis. Pulmonary fun-
ction test with decreasing diffusing capacity of the
lung for carbon monoxide > 15% and decreasing
total lung capacity were noted in patient 1. Con-
gestive heart failure has a high prevalence rate
among these patients with amiodarone-related
pulmonary toxicity and the radiographic appear-
ance of pulmonary edema may be mimicked by
amiodarone toxicity. Therefore, if heart failure can-
not be easily excluded, the pulmonary capillary
wedge pressure should be measured. Serum assay
of brain natriuretic peptide could also be used as a
sensitive test to detect LV dysfunction. A diagnosis
of amiodarone-induced pulmonary pneumonitis
could be suspected if there is no elevation in the
brain natriuretic peptide level in comparison with
the patient’s baseline values associated with clini-
cal deterioration.15 None of our patients were in
congestive heart failure by clinical examinations
(absence of jugular venous distension or S3). No
patient underwent bronchoscopy and biopsy due
to the family’s decision. Amiodarone pulmonary
toxicity may mimic infection or accompany in-
fection and in such cases, a careful search must
be undertaken for an offending organism. In pa-
tient 2, pneumonia might be accompanied by
amiodarone pneumonitis, the clinical improve-
ment of patient 2 could be attributed to the effects
of steroid and discontinuation of amiodarone use
during the course of treatment. Since the elimina-
tion rate of amiodarone and its metabolite diethyl
amiodarone is extremely slow, which will efflux
within 6–12 months,16 thus, prompt reversal of
pulmonary side-effects cannot be expected after
withdrawal of the drug. Furthermore, steroid ther-
apy must necessarily be continued for many weeks
or months while the drug remains in the blood
and tissues. Effective treatment of amiodarone
associated pneumonitis must include prompt
withdrawal of amiodarone and institution of
steroid therapy.17
Amiodarone pulmonary abnormalities could
develop in patients even under low-dose therapy.
Drug-induced injury should be considered in all
patients taking amiodarone who develop respira-
tory symptoms. Besides, amiodarone pneumonitis
may be lethal if unrecognized and untreated. It is
vital therefore to recognize it at an early stage and
necessary to perform chest radiography every 1 to
2 months for the 1st year after the initiation of ami-
odarone therapy. This could help detect the earli-
est pulmonary changes and take appropriate steps
such as steroid treatment to prevent further deterio-
ration of pulmonary function. We have shown that
amiodarone 200 mg/day for around half a year
could lead to interstitial pneumonitis and this
serves as a reminder of the clinical uncertainties of
low-dose amiodarone usage. Besides, compared
with the previous studies of amiodarone-related
pneumonitis (Table 2),6–12 improvements both
clinically and in chest radiographs usually occur-
red several months after cessation of amio-
darone and under steroid treatment. The rapid
improvement in our patients might imply that
low-dose amiodarone-related pneumonitis could
be reversed by early detection and early treatment
compared with high-dose amiodarone-related
pneumonitis. Our report reminds clinicians to rec-
ognize that low-dose amiodarone (200 mg) is
associated with some risk of developing pulmo-
nary toxicity even under short-term use (6 months).
Early diagnosis and treatment are mandatory to
reverse this potentially fatal adverse reaction.
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